ArticleNature aging2024
Preexisting senescent fibroblasts in the aged bladder create a tumor-permissive niche through CXCL12 secretion.
Abstract read
In one paragraph
Article in Nature aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Immune niche composed of C1QNature communications · 2026Article
- Epigenetic dynamics of cellular senescence: From mechanistic insights to precision senotherapy.Chinese medical journal · 2026Review
- Characterization of p16-positive stromal cells in age-related cardiac disorders.Journal of biochemistry · 2026Article
- Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026Review
- The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.Cancer research · 2026Article
- The relationship between CXC chemokines and cellular senescence: from mechanisms to therapy.Biogerontology · 2026Review
- Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications.Cancer cell · 2026Review
- Cancer-cell-secreted DDAH1 induces TGF-β1/Smad3 signaling pathway to promote fibrosis and aging in lung.Nature aging · 2026Article
- Unleashing endogenous regeneration by senolytics.Journal of translational medicine · 2025Review
- Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025Review
- Stromal senescence contributes to age-related increases in cancer.Nature reviews. Cancer · 2025Review
- Fibroblast activation and heterogeneity in fibrotic disease.Nature reviews. Nephrology · 2025Review
- Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Extracellular vesicles from ovarian cancer cells induce senescent lipid-laden macrophages to facilitate omental metastasis.Journal of nanobiotechnology · 2025Article
- Transforming Cancer Therapy: Unlocking the Potential of Targeting Vascular and Stromal Cells in the Tumor Microenvironment.Cancer research · 2025Review
- CXCL12 links bladder cancer and diabetes as a potential biomarker.Scientific reports · 2025Article
- Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.BMC cancer · 2025Article
- Article
- Cancer-associated fibroblasts: dual roles from senescence sentinels to death regulators and new dimensions in therapy.Frontiers in immunology · 2025Review
- Cellular senescence as a source of chronic microinflammation that promotes the aging process.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Satoru MeguroDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0003-2179-5028
Yoshikazu JohmuraDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. johmuray@staff.kanazawa-u.ac.jp.ORCID 0000-0002-6812-9607
Teh-Wei WangDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Satoshi KawakamiDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Shota TanimotoDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Satotaka OmoriDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Yuki T OkamuraDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Seiji HoshiDepartment of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Emina KayamaDepartment of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Seira HatakeyamaDivision of Clinical Genome Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Satoshi YamazakiDivision of Stem Cell Biology, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4249-3854
Eigo ShimizuDivision of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0462-8631
Yoshiyuki KojimaDepartment of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. ykojima@fmu.ac.jp.ORCID 0000-0001-8000-0868
Makoto NakanishiDivision of Cancer Cell Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. mkt-naka@g.ecc.u-tokyo.ac.jp.ORCID 0000-0002-6707-3584
Funding
Japan Agency for Medical Research and Development (AMED) JP20ck010655hJapan Agency for Medical Research and Development (AMED) JP20gm5010001sJapan Agency for Medical Research and Development (AMED) JP21gm6410014hJapan Agency for Medical Research and Development (AMED) JP23gm1410013hJapan Agency for Medical Research and Development (AMED) JP23zf0127003hMEXT | Japan Society for the Promotion of Science (JSPS) JP19H03431MEXT | Japan Society for the Promotion of Science (JSPS) JP19H05740MEXT | Japan Society for the Promotion of Science (JSPS) JP20H00514MEXT | Japan Society for the Promotion of Science (JSPS) JP20H04940MEXT | Japan Society for the Promotion of Science (JSPS) JP20K21497
Abstract
Aging is a major risk factor for cancer, but the precise mechanism by which aging promotes carcinogenesis remains largely unknown. Here, using genetically modified mouse models, we show that p16
Indexed as
Cancer-Associated FibroblastsCellular SenescenceChemokine CXCL12Urinary BladderUrinary Bladder NeoplasmsAgingAnimalsCyclin-Dependent Kinase Inhibitor p16FemaleFibroblastsHumansMaleMiceTumor MicroenvironmentChemokine CXCL12CXCL12 protein, humanCxcl12 protein, mouseCyclin-Dependent Kinase Inhibitor p16
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.